Symbols / PPBT $4.24 +3.67%
PPBT Chart
About
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.40M |
| Enterprise Value | 7.56B | Income | -26.39M | Sales | — |
| Book/sh | 0.01 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -6.62 | PEG | — |
| P/S | — | P/B | 848.00 | P/C | — |
| EV/EBITDA | -1116.66 | EV/Sales | — | Quick Ratio | 1.24 |
| Current Ratio | 1.27 | Debt/Eq | 2.53 | LT Debt/Eq | — |
| EPS (ttm) | -461.00 | EPS next Y | -0.64 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-13 08:00 | ROA | -15.97% |
| ROE | -124.46% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 903.04K |
| Shs Float | 1.72B | Short Float | 0.96% | Short Ratio | 0.71 |
| Short Interest | — | 52W High | 30.50 | 52W Low | 3.70 |
| Beta | -0.74 | Avg Volume | 13.57K | Volume | 6.04K |
| Target Price | $30.00 | Recom | Strong_buy | Prev Close | $4.09 |
| Price | $4.24 | Change | 3.67% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$30.00
Mean price target
2. Current target
$3.99
Latest analyst target
3. DCF / Fair value
$-13.31
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.99
Low
$30.00
High
$30.00
Mean
$30.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-13 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $33 |
| 2024-09-20 | main | HC Wainwright & Co. | Buy → Buy | $33 |
| 2024-08-19 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-07-11 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-21 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-04-26 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-03-07 | main | Chardan Capital | Buy → Buy | $11 |
| 2024-03-05 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-02-27 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-11-21 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-08-31 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-08-30 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-07-21 | init | JonesTrading | — → Buy | $8 |
| 2023-05-17 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-05-17 | reit | Chardan Capital | Buy → Buy | $11 |
| 2023-02-09 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2023-02-09 | reit | Chardan Capital | — → Buy | $11 |
| 2022-10-17 | init | HC Wainwright & Co. | — → Buy | $7 |
| 2022-09-08 | init | Chardan Capital | — → Buy | $11 |
- Cancer immunotherapy company Purple Biotech keeps its Nasdaq listing - Stock Titan ue, 17 Mar 2026 11
- Purple Biotech Ltd. (PPBT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Sat, 14 Mar 2026 00
- H.C. Wainwright cuts Purple Biotech stock price target to $30 - Investing.com Mon, 16 Mar 2026 11
- Purple Biotech halts two cancer drugs to push new 3-target antibody platform - Stock Titan Fri, 13 Mar 2026 12
- Purple Biotech regains compliance with Nasdaq - marketscreener.com ue, 17 Mar 2026 12
- PPBT (Purple Biotech) NonCurrent Deferred Revenue : $0.00 Mil (As of Sep. 2025) - GuruFocus hu, 12 Mar 2026 19
- Purple Biotech Posts 2025 Loss, Doubles Down on CAPTN-3 Immunotherapy Platform - TipRanks Fri, 13 Mar 2026 12
- Purple Biotech Ltd. Announces ADS Ratio Change to Regain Nasdaq Compliance Effective March 2, 2026 - Quiver Quantitative Wed, 25 Feb 2026 08
- Purple Biotech Announces CEO Transition - ChartMill Fri, 13 Mar 2026 12
- Purple Biotech CEO steps aside for health, shifts to dealmaking role - Stock Titan Fri, 13 Mar 2026 12
- Purple Biotech stock soars after manufacturing milestone for tri-specific antibody - Investing.com Wed, 29 Oct 2025 07
- Purple Biotech (PPBT) Focuses on CAPTN-3 Platform Development - GuruFocus Fri, 13 Mar 2026 18
- Why Is Purple Biotech Stock (PPBT) Up 95% Today? - TipRanks Wed, 29 Oct 2025 07
- Purple Biotech consolidates U.S. ADSs 1-for-10 to meet Nasdaq $1 rule - Stock Titan Wed, 25 Feb 2026 08
- Purple Biotech (NASDAQ: PPBT) unveils CAPTN-3 data on tumor regression and PD-1–resistant models - Stock Titan hu, 11 Dec 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -10.79M | -23.73M | -21.80M | -17.38M |
| TotalUnusualItems | 3.74M | 4.00M | 307.00K | -133.00K |
| TotalUnusualItemsExcludingGoodwill | 3.74M | 4.00M | 307.00K | -133.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.24M | -19.88M | -21.67M | -17.74M |
| ReconciledDepreciation | 186.00K | 197.00K | 201.00K | 231.00K |
| EBITDA | -7.05M | -19.72M | -21.49M | -17.52M |
| EBIT | -7.24M | -19.92M | -21.69M | -17.75M |
| NetInterestIncome | -212.00K | -1.71M | 536.00K | 241.00K |
| InterestExpense | 41.00K | 56.00K | 67.00K | 79.00K |
| InterestIncome | 260.00K | 474.00K | 532.00K | 320.00K |
| NormalizedIncome | -10.98M | -23.88M | -21.98M | -17.61M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.24M | -19.88M | -21.67M | -18.38M |
| TotalExpenses | 10.80M | 22.27M | 22.60M | 17.93M |
| TotalOperatingIncomeAsReported | -11.01M | -22.27M | -22.60M | -17.93M |
| DilutedAverageShares | 1.64M | 1.11M | 904.05K | 878.40K |
| BasicAverageShares | 1.64M | 1.11M | 904.05K | 878.40K |
| DilutedEPS | -4.44 | -17.96 | -24.00 | -21.00 |
| BasicEPS | -4.44 | -17.96 | -24.00 | -21.00 |
| DilutedNIAvailtoComStockholders | -7.24M | -19.88M | -21.67M | -18.38M |
| NetIncomeCommonStockholders | -7.24M | -19.88M | -21.67M | -18.38M |
| NetIncome | -7.24M | -19.88M | -21.67M | -18.38M |
| MinorityInterests | 39.00K | 97.00K | 92.00K | 84.00K |
| NetIncomeIncludingNoncontrollingInterests | -7.28M | -19.98M | -21.76M | -18.47M |
| NetIncomeDiscontinuousOperations | 0.00 | 0.00 | -642.00K | |
| NetIncomeContinuousOperations | -7.28M | -19.98M | -21.76M | -17.83M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -7.28M | -19.98M | -21.76M | -17.83M |
| OtherIncomeExpense | 3.74M | 4.00M | 307.00K | -133.00K |
| SpecialIncomeCharges | -202.00K | 0.00 | 0.00 | |
| WriteOff | 202.00K | 0.00 | 0.00 | |
| GainOnSaleOfSecurity | 3.94M | 4.00M | 307.00K | -133.00K |
| NetNonOperatingInterestIncomeExpense | -212.00K | -1.71M | 536.00K | 241.00K |
| TotalOtherFinanceCost | 431.00K | 2.12M | -71.00K | |
| InterestExpenseNonOperating | 41.00K | 56.00K | 67.00K | 79.00K |
| InterestIncomeNonOperating | 260.00K | 474.00K | 532.00K | 320.00K |
| OperatingIncome | -10.80M | -22.27M | -22.60M | -17.93M |
| OperatingExpense | 10.80M | 22.27M | 22.60M | 17.93M |
| OtherOperatingExpenses | 62.00K | 196.00K | 120.00K | 55.00K |
| DepreciationAmortizationDepletionIncomeStatement | 186.00K | 197.00K | 201.00K | 231.00K |
| DepreciationAndAmortizationInIncomeStatement | 186.00K | 197.00K | 201.00K | 231.00K |
| DepreciationIncomeStatement | 186.00K | 197.00K | 201.00K | 231.00K |
| ResearchAndDevelopment | 7.62M | 17.03M | 16.32M | 11.83M |
| SellingGeneralAndAdministration | 2.94M | 4.84M | 5.96M | 5.82M |
| GeneralAndAdministrativeExpense | 2.94M | 4.84M | 5.96M | 5.82M |
| OtherGandA | 918.00K | 1.15M | 1.32M | 1.50M |
| SalariesAndWages | 2.02M | 3.69M | 4.64M | 4.32M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 1.00 | 1.00 | 1.00 | |
| OrdinarySharesNumber | 517.13M | 252.38M | 184.82M | 178.00M |
| ShareIssued | 517.13M | 252.38M | 184.82M | 178.00M |
| TotalDebt | 183.00K | 351.00K | 515.00K | 749.00K |
| TangibleBookValue | 5.02M | 6.16M | 26.23M | 44.34M |
| InvestedCapital | 32.86M | 34.21M | 46.91M | 64.83M |
| WorkingCapital | 4.92M | 6.09M | 26.20M | 44.22M |
| NetTangibleAssets | 5.02M | 6.16M | 26.23M | 44.34M |
| CapitalLeaseObligations | 183.00K | 351.00K | 515.00K | 749.00K |
| CommonStockEquity | 32.86M | 34.21M | 46.91M | 64.83M |
| TotalCapitalization | 32.86M | 34.21M | 46.91M | 64.83M |
| TotalEquityGrossMinorityInterest | 32.91M | 34.30M | 47.10M | 65.11M |
| MinorityInterest | 51.00K | 90.00K | 187.00K | 279.00K |
| StockholdersEquity | 32.86M | 34.21M | 46.91M | 64.83M |
| OtherEquityInterest | 30.02M | 38.55M | 38.18M | 36.88M |
| GainsLossesNotAffectingRetainedEarnings | -98.00K | -79.00K | -104.00K | -98.00K |
| OtherEquityAdjustments | -98.00K | -79.00K | -104.00K | -98.00K |
| RetainedEarnings | -144.69M | -137.45M | -117.57M | -95.91M |
| AdditionalPaidInCapital | 147.63M | 133.18M | 126.41M | 123.95M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 4.13M | 10.01M | 7.52M | 5.09M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 140.00K | 304.00K | 466.00K | 842.00K |
| DerivativeProductLiabilities | 2.52M | 0.00 | ||
| EmployeeBenefits | 140.00K | 141.00K | 145.00K | 292.00K |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 140.00K | 141.00K | 145.00K | 292.00K |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 163.00K | 321.00K | 550.00K |
| LongTermCapitalLeaseObligation | 0.00 | 163.00K | 321.00K | 550.00K |
| CurrentLiabilities | 3.99M | 9.70M | 7.06M | 4.25M |
| OtherCurrentLiabilities | 1.15M | 2.52M | ||
| CurrentDebtAndCapitalLeaseObligation | 183.00K | 188.00K | 194.00K | 199.00K |
| CurrentCapitalLeaseObligation | 183.00K | 188.00K | 194.00K | 199.00K |
| PayablesAndAccruedExpenses | 2.65M | 7.00M | 6.86M | 4.05M |
| CurrentAccruedExpenses | 818.00K | 2.79M | 4.03M | 1.97M |
| Payables | 1.84M | 4.21M | 2.83M | 2.08M |
| OtherPayable | 65.00K | 53.00K | 91.00K | 84.00K |
| DuetoRelatedPartiesCurrent | 317.00K | 620.00K | 607.00K | 527.00K |
| AccountsPayable | 1.46M | 3.53M | 2.13M | 1.47M |
| TotalAssets | 37.04M | 44.30M | 54.62M | 70.20M |
| TotalNonCurrentAssets | 28.13M | 28.51M | 21.37M | 21.73M |
| NonCurrentPrepaidAssets | 0.00 | 160.00K | ||
| InvestmentsAndAdvances | 0.00 | 187.00K | ||
| OtherInvestments | 0.00 | 187.00K | ||
| GoodwillAndOtherIntangibleAssets | 27.84M | 28.04M | 20.68M | 20.48M |
| OtherIntangibleAssets | 27.84M | 28.04M | ||
| NetPPE | 288.00K | 470.00K | 682.00K | 896.00K |
| GrossPPE | 288.00K | 470.00K | 682.00K | 896.00K |
| OtherProperties | 124.00K | 154.00K | 215.00K | 277.00K |
| BuildingsAndImprovements | 164.00K | 316.00K | 467.00K | 619.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 8.91M | 15.79M | 33.26M | 48.47M |
| OtherCurrentAssets | 109.00K | 171.00K | 146.00K | 268.00K |
| PrepaidAssets | 205.00K | 997.00K | 1.00M | |
| Receivables | 275.00K | 205.00K | 997.00K | 1.00M |
| OtherReceivables | 275.00K | 205.00K | 997.00K | 1.00M |
| CashCashEquivalentsAndShortTermInvestments | 8.52M | 15.41M | 32.11M | 47.20M |
| OtherShortTermInvestments | 1.12M | 923.00K | 17.08M | 36.31M |
| CashAndCashEquivalents | 7.40M | 14.49M | 15.03M | 10.89M |
| CashFinancial | 14.49M | 15.03M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -14.37M | -19.93M | -16.96M | -15.37M |
| RepaymentOfDebt | -183.00K | -168.00K | -165.00K | -153.00K |
| IssuanceOfCapitalStock | 5.81M | 1.56M | 1.50M | 564.00K |
| CapitalExpenditure | -3.00K | -228.00K | -115.00K | |
| EndCashPosition | 7.40M | 14.49M | 15.03M | 10.89M |
| BeginningCashPosition | 14.49M | 15.03M | 10.89M | 11.25M |
| EffectOfExchangeRateChanges | -4.00K | 54.00K | -153.00K | -24.00K |
| ChangesInCash | -7.08M | -595.00K | 4.29M | -333.00K |
| CashFlowFromDiscontinuedOperation | -374.00K | |||
| FinancingCashFlow | 6.77M | 5.45M | 1.11M | 1.51M |
| CashFromDiscontinuedFinancingActivities | 0.00 | 0.00 | ||
| CashFlowFromContinuingFinancingActivities | 6.77M | 5.45M | 1.11M | 1.51M |
| NetOtherFinancingCharges | -836.00K | -890.00K | -152.00K | -24.00K |
| InterestPaidCFF | -44.00K | -56.00K | -67.00K | -75.00K |
| ProceedsFromStockOptionExercised | 2.03M | 5.00M | 0.00 | 1.20M |
| CashDividendsPaid | 0.00 | 0.00 | 0.00 | 0.00 |
| NetCommonStockIssuance | 5.81M | 1.56M | 1.50M | 564.00K |
| CommonStockIssuance | 5.81M | 1.56M | 1.50M | 564.00K |
| NetIssuancePaymentsOfDebt | -183.00K | -168.00K | -165.00K | -153.00K |
| NetLongTermDebtIssuance | -183.00K | -168.00K | -165.00K | -153.00K |
| LongTermDebtPayments | -183.00K | -168.00K | -165.00K | -153.00K |
| InvestingCashFlow | 509.00K | 13.88M | 19.91M | 13.41M |
| CashFromDiscontinuedInvestingActivities | 0.00 | 0.00 | ||
| CashFlowFromContinuingInvestingActivities | 509.00K | 13.88M | 19.91M | 13.41M |
| InterestReceivedCFI | 320.00K | 755.00K | 324.00K | 359.00K |
| NetInvestmentPurchaseAndSale | 189.00K | 16.68M | 19.82M | 13.16M |
| SaleOfInvestment | 189.00K | 16.68M | 19.82M | 13.16M |
| PurchaseOfInvestment | 0.00 | |||
| NetBusinessPurchaseAndSale | 0.00 | -3.55M | 0.00 | 0.00 |
| SaleOfBusiness | 0.00 | 0.00 | ||
| PurchaseOfBusiness | 0.00 | -3.55M | 0.00 | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -202.00K | 0.00 |
| PurchaseOfIntangibles | 0.00 | 0.00 | -202.00K | 0.00 |
| NetPPEPurchaseAndSale | 0.00 | -3.00K | -26.00K | -115.00K |
| PurchaseOfPPE | 0.00 | -3.00K | -26.00K | -115.00K |
| OperatingCashFlow | -14.37M | -19.93M | -16.73M | -15.25M |
| CashFromDiscontinuedOperatingActivities | 0.00 | 0.00 | -374.00K | |
| CashFlowFromContinuingOperatingActivities | -14.37M | -19.93M | -16.73M | -14.88M |
| ChangeInWorkingCapital | -4.33M | 274.00K | 3.25M | 744.00K |
| ChangeInOtherWorkingCapital | -162.00K | 11.00K | 27.00K | |
| ChangeInOtherCurrentAssets | 96.00K | 178.00K | 313.00K | -316.00K |
| ChangeInPayablesAndAccruedExpense | -4.43M | 258.00K | 2.93M | 1.03M |
| ChangeInPayable | -4.43M | 258.00K | 2.93M | 1.03M |
| ChangeInAccountPayable | -2.08M | 1.33M | 799.00K | 399.00K |
| ChangeInReceivables | 313.00K | -316.00K | ||
| ChangesInAccountReceivables | 313.00K | -316.00K | ||
| OtherNonCashItems | -3.73M | -2.29M | -843.00K | -108.00K |
| StockBasedCompensation | 582.00K | 1.88M | 2.41M | 2.08M |
| AssetImpairmentCharge | 202.00K | 0.00 | 0.00 | |
| DepreciationAmortizationDepletion | 186.00K | 197.00K | 201.00K | 231.00K |
| DepreciationAndAmortization | 186.00K | 197.00K | 201.00K | 231.00K |
| Depreciation | 186.00K | 197.00K | 201.00K | 231.00K |
| NetIncomeFromContinuingOperations | -7.28M | -19.98M | -21.76M | -17.83M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for PPBT
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|